Liu et al. established a prognostic model that combined molecular biomarkers (TPX2 and MMP12) and several meaningful clinical features and exhibited a higher survival prediction performance (AUC = 0.771) than TNM staging systems in postoperative NSCLC patients (Liu et al., 2018). This evidence concerns the gene MMP12 and non-small cell lung carcinoma.